Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.

TL;DR: Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy by enhancing immunogenic cell death and promoting T cell infiltration.

TL;DR: Embryonic miRNAs have the potential to serve as valuable biomarkers and therapeutic targets for GBC.

TL;DR: In this paper , the frontiers of diagnostic and therapeutic applications (theranostics) of QDs, especially in advanced medical fields such as regenerative medicine, oncology, and infectious diseases, are outlined.

TL;DR: The overview illustrates the significant advances in nanomedicine, underscoring its role in transcending the constraints of conventional PDAC therapies and diagnostics.

TL;DR: A liposomal vaccine carrier that selectively delivers tumor antigens and Toll-like receptor agonists to human CD169/Siglec-1+ antigen-presenting cells (APCs) through the incorporation of gangliosides that are natural ligands of CD169 is formulated.

TL;DR: Molecular evidence is provided showing that the activation of the Hif-1α and NF-κB loop is mechanistically linked with the chemoresistance phenotype (EMT phenotype) of pancreatic cancer cells under hypoxic conditions, suggesting that the inactivation of HIF-1 α and NF -κB signaling by novel strategies may be a potential targeted therapeutic approach for overcoming EMT and Chemoresistance induced by hypoxia.

TL;DR: It is demonstrated that a peptide based, oligonucleotide condensing, endosomolytic nanoparticle (NP) system is avidly taken up by cancer cells in vitro, can deliver KRAS-specific siRNA, inhibit KRAS expression, and reduce cell viability, and can deliver siRNA to the tumor microenvironment.

TL;DR: In this phase II study, the addition of cisplatin and capecitabine to the AG backbone was feasible and yielded promising results in terms of disease control without detrimental impact on tolerability.